Pharma News: Label Change to Bydureon, Inspire Trial Fails Monday, March 15, 12:41 PM ET
The Food and Drug Administration is demanding clarifications on the labeling and manufacturing process for Bydureon, a new drug candidate of Amylin Pharmaceuticals (AMLN), Eli Lilly (NYSE:LLY) and Alkermes (NASDAQ:ALKS).
The FDA would like changes made to clarify the product labeling and asked questions about the drug’s manufacturing process.
Bydureon is a once weekly form of the Type II diabetes drug Byetta, which already has annual sales of $700 million.
The drug has been developed by Amylin and Lilly, and uses controlled release technology from Alkermes.
The companies will respond to the FDA’s requests within a few weeks.
Amylin shares are trading over 8 percent Monday, while Lilly shares are trading about flat.
Also in the pharma industry this morning, Inspire Pharmaceuticals (ISPH) said today two Phase II clinical trials of its blepharitis drug Azasite failed to meet primary endpoints. Blepharitis is inflammation of the eyelids.
Interesting UBX Put And Call Options For March 19th Friday, January 15, 11:52 AM ET, by Market News Video Staff Investors in Unity Biotechnology Inc (UBX) saw new options begin trading this week, for the ...
First Week of KERN March 19th Options Trading Friday, January 15, 11:52 AM ET, by Market News Video Staff Investors in Akerna Corp (KERN) saw new options become available this week, for the March ...
First Week of EOLS March 19th Options Trading Friday, January 15, 11:52 AM ET, by Market News Video Staff Investors in Evolus Inc (EOLS) saw new options become available this week, for the March ...
First Week of IQ September 17th Options Trading Friday, January 15, 11:52 AM ET, by Market News Video Staff Investors in iQIYI Inc (IQ) saw new options become available this week, for the September ...
First Week of SURF March 19th Options Trading Friday, January 15, 11:52 AM ET, by Market News Video Staff Investors in Surface Oncology Inc (SURF) saw new options become available this week, for the ...
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.